Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Wilmington Healthcare appoints new Solutions Director

May 27, 2021 | NHS, Promotion, healthcare 

Kirsty Fryer has been promoted to the role of Solutions Director for Wilmington Healthcare

Wilmington Healthcare, a market leader in the provision of data, insight and intelligence for pharma and medtech companies, has announced the promotion of Kirsty Fryer to the role of Solutions Director.

In her new role, Kirsty will be responsible for the Quantis portfolio of products offered by Wilmington Healthcare, leading the team as they continue to deliver outstanding service and solutions to the organisation’s customers. Bringing together all disciplines, from analytical, development, commercial and marketing to underpin Wilmington Healthcare’s ambitious growth plans, Kirsty will ensure customers continue to receive trusted insight and real-world data solutions.

Kirsty steps up to the role having been Solutions Consultant since November 2017 and a valued member of the Wilmington Healthcare team since 2015. In this time, she has developed her career from bespoke researcher supporting the organisation’s understanding of the healthcare ecosystem before joining the solutions team working with real-world evidence – transforming data-led insight into core messages and potential implications. With a PhD in Neurophysiology from the University of Nottingham and currently undertaking an MBA with senior leadership focus she brings a wealth of expertise to the role alongside her existing client relationships.

Welcoming the appointment Jonathan Carney, of Wilmington Healthcare, says: “Kirsty has been a huge asset to Wilmington Healthcare since she joined the company in 2015. Her promotion to lead one of our key growth products in the role of Solutions Director is recognition for her passion, energy and commitment in delivering the very best for our customers combined with her extensive knowledge of our products and the impact they help to make in shaping sustainable commercial and partnership strategies for our customers. Through Kirsty’s appointment we will be building upon our market credentials as a trusted, leading organisation in the Healthcare Insight arena.”

Kirsty Fryer adds: ‘I’m proud of my work over the last five years within Wilmington Healthcare and I’m excited to guide our fantastic team as we continue to provide bespoke, real-world insight to meet the individual needs of our customers in parallel with the evolving needs of the NHS in this new era of healthcare impacted by the COVID-19 pandemic.”

This content was provided by Wilmington Healthcare

Company Details

Wilmington Healthcare

Wilmington Healthcare

Email
Website

 Latest Content from  Wilmington Healthcare 

Hear from her: Women's Health Faces Some Difficult Headwinds. Here's How We Can Move Forward

Considering a portfolio review?

Are you considering a portfolio review for your established pharmaceutical brands? Wondering if you should put some activity behind them? At CHASE our experienced team will ensure you maximise your...

UNDERSTANDING THE ROLE OF PLACE WITHIN THE NEW NHS: FIVE THINGS INDUSTRY NEEDS TO KNOW

Operating a level below system, “place” is an increasingly important unit of NHS organisation, yet it remains an evolving concept that is not always well-understood among industry practitioners. In this...

MISSION CRITICAL: HOW PHARMA CAN HELP THE NHS IMPROVE CARE FOR OLDER PEOPLE

With around two-thirds of all hospital beds occupied by over-65s, the care of older patients has long been recognised as key to the sustainability of the NHS. So how is...

ALL CHANGE FOR SPECIALISED COMMISSIONING: FOUR THINGS INDUSTRY NEEDS TO KNOW ABOUT THE LATEST REFORMS

With a recent NHSEI policy document confirming that a major shake-up of arrangements for Specialised Commissioning is imminent, Oli Hudson, Content Director at Wilmington Healthcare (wilmingtonhealthcare.com), describes the key changes...

HOW DID COVID-19 AFFECT PRESCRIBING BEHAVIOURS? FIVE KEY FINDINGS FROM A NEW STATE OF THE NATION REVIEW

Published earlier this month, Wilmington Healthcare’s new State of the Nation report draws on a raft of data from across primary and secondary care to show what actually happened to...

ALL SYSTEMS GO: UNDERSTANDING WHO’S WHO IN THE NEW NHS LANDSCAPE

With the Health and Care Act safely passed, Oli Hudson introduces six key stakeholders that will loom large in the new landscape.

Spending on anti-depressants soars as the pandemic’s effect on NHS prescribing patterns is revealed

Wilmington Healthcare’s State of the Nation prescribing report shows that spending on sertraline, commonly used to treat depression and anxiety, increased by 305.5% between 2019/20 and 2020/21 while overall spend...

EQUAL FOOTING: HOW PHARMA CAN HELP THE NHS TO ACT ON HEALTH INEQUALITIES

As the NHS puts a renewed focus on reducing health inequalities, Oli Hudson looks at what opportunities this might it bring for Industry and how it can best play its...

UNDERSTANDING THE NEW VALUE PROPOSITION FOR THE NHS

Industry needs a new way of describing its commercial propositions in response to the changing NHS landscape, argues Wilmington Healthcare’s Oli Hudson. This ‘new value proposition’ needs to be reflected...